IN2014MN01940A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01940A
IN2014MN01940A IN1940MUN2014A IN2014MN01940A IN 2014MN01940 A IN2014MN01940 A IN 2014MN01940A IN 1940MUN2014 A IN1940MUN2014 A IN 1940MUN2014A IN 2014MN01940 A IN2014MN01940 A IN 2014MN01940A
Authority
IN
India
Prior art keywords
getting
risk
cardiovascular event
level
neurotensin
Prior art date
Application number
Other languages
English (en)
Inventor
Andreas Bergmann
Olle Melander
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of IN2014MN01940A publication Critical patent/IN2014MN01940A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/323Arteriosclerosis, Stenosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1940MUN2014 2012-03-08 2013-03-08 IN2014MN01940A (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261608376P 2012-03-08 2012-03-08
EP12158678 2012-03-08
EP12165057 2012-04-20
PCT/EP2013/054799 WO2013132088A1 (en) 2012-03-08 2013-03-08 A method for predicting the risk of getting a cardiovascular event in a female subject

Publications (1)

Publication Number Publication Date
IN2014MN01940A true IN2014MN01940A (de) 2015-07-10

Family

ID=49115969

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1940MUN2014 IN2014MN01940A (de) 2012-03-08 2013-03-08

Country Status (7)

Country Link
US (1) US20150118236A1 (de)
EP (1) EP2823318B1 (de)
JP (1) JP6431373B2 (de)
CN (1) CN103308673B (de)
IN (1) IN2014MN01940A (de)
RU (1) RU2652304C2 (de)
WO (1) WO2013132088A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3002589A1 (de) * 2014-10-01 2016-04-06 sphingotec GmbH Verfahren zur stratifizierung einer frau zur hormonersatztherapie
SG11201706460QA (en) * 2015-02-27 2017-09-28 Sphingotec Gmbh A method for predicting the risk of obesity in a subject
CA3079931A1 (en) 2017-10-24 2019-05-02 Sphingotec Gmbh Selenoprotein p for prediction of a first cardiovascular event
CN109678958B (zh) * 2019-01-31 2022-03-18 重庆探生科技有限公司 一种人NT-proBNP特异性重组羊单克隆抗体及其制备方法和应用
RU2718285C1 (ru) * 2019-05-31 2020-04-01 федеральное государственное бюджетное образовательное учреждение высшего образования "Новосибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НГМУ Минздрава России) Способ прогнозирования риска развития инсульта у мужчин, работающих в условиях воздействия общей вибрации
WO2022101937A1 (en) * 2020-11-12 2022-05-19 Shah Komal An integrated health data capture and analysis based device for evaluation, diagnosis and prognosis of heart failure

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US6352862B1 (en) * 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
EP0854934A4 (de) * 1995-08-18 2000-09-06 Donald W Landry Nachweis von organischen verbindungen regulation von durch antikörper katalysierten reaktionen
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE60233949D1 (de) * 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
IL160289A0 (en) 2001-08-30 2004-07-25 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins
ES2528254T3 (es) 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
US7634360B2 (en) * 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
JP4838794B2 (ja) * 2004-06-15 2011-12-14 エフ.ホフマン−ラ ロシュ アーゲー 心臓毒性医薬の結果として心血管合併症に罹患するリスクを診断するための心臓ホルモンの使用
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
CA2742241C (en) 2008-11-03 2019-12-10 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
EP2374003B1 (de) 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung, prognosebeurteilung und erkennung von brustkrebs
ES2643033T3 (es) * 2009-05-05 2017-11-21 B.R.A.H.M.S Gmbh Estratificación basada en la hormona vasoactiva de los pacientes que sufren de enfermedades relacionadas con la función/disfunción endotelial
BR112012004314A2 (pt) 2009-08-27 2016-11-29 Covagen Ag compostos de ligação a il-17 e usos medicinais desses compostos
US8846414B2 (en) * 2009-09-29 2014-09-30 Advanced Liquid Logic, Inc. Detection of cardiac markers on a droplet actuator
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
EP2580236B1 (de) 2010-06-08 2019-04-03 Pieris Pharmaceuticals GmbH Muteine von tränen-lipocalin mit affinität für il-4 r alpha

Also Published As

Publication number Publication date
EP2823318A1 (de) 2015-01-14
EP2823318B1 (de) 2016-08-10
JP2015511007A (ja) 2015-04-13
JP6431373B2 (ja) 2018-11-28
WO2013132088A1 (en) 2013-09-12
CN103308673B (zh) 2017-05-31
RU2014140430A (ru) 2016-04-27
RU2652304C2 (ru) 2018-04-25
CN103308673A (zh) 2013-09-18
WO2013132088A4 (en) 2013-11-07
US20150118236A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
IN2014MN01940A (de)
WO2014053466A3 (en) System and method for assessing risk associated with a glucose state
BR112013032183A2 (pt) sistema e método de avaliação de recursos
EP4462120A3 (de) Verfahren zur vorhersage der antikrebsreaktion
IN2014CN04326A (de)
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
PH12013502340A1 (en) Biomarkers for hedgehog inhibitor therapy
NZ630421A (en) Biomarkers predictive for clinical response for glatiramer acetate
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2014200912A3 (en) Mathematical processes for determination of peptidase cleavage
IL230896B (en) Micro-rna biological markers for use in detecting the presence or risk of a lung tumor or an aggressive lung tumor
WO2014172390A3 (en) Methods for detecting cancer metastasis
WO2012135227A3 (en) Methods and systems for assessing exposure to heavy metals
FR2992620B1 (fr) Train et procede de determination de la composition d'un tel train en securite
MX2015015328A (es) Deteccion de grietas de borde.
FR2996192B1 (fr) Procede de determination de l'etat d'usure d'une piece et d'information d'un client
MX2022013471A (es) Metodo y composiciones de deteccion y cuantificacion de acido nucleico.
IN2014MN01936A (de)
WO2016066862A3 (en) A method for predicting the risk of obesity in a subject
IN2015DN01646A (de)
IN2014MN01937A (de)
GB201101400D0 (en) Detection method
HK1231512A1 (zh) 检测样本中多种核酸的方法
WO2013106851A3 (en) Syncollin, pancreatic triacylglycerol lipase, and other biomarkers for diabetes
WO2014023952A3 (en) Interleukin-18 inhibitor for use in prevention and treatment of osteoarthritis